Objective To investigate the effects of bisphosphonate on the proliferator-activated receptor γ(PRARγ)expression of glucocorticoid-induced osteoporosis. Methods ① Twenty-two cases of systemic lupus erythematosus(SLE)patients with glucocorticoids(＞0.5 mg·kg-1 ·d-1)were divided into 2 groups: 9 cases in the treatment group in which patients received alendronate 70 mg qw., 13 cases in the control group without anti-osteoporosis treatment. All of the patients had bone marrow puncture after 24 weeks, bone tissues were embedded, sliced, and the value of average optical density of PPARγwas tested with immunohistochemistry. ② Human bone mesenchymal stem cells were cultured in the same conditions and stimulated to adipocytes. During the adipogenic process, the cells were divided into four groups, three of which were experimental groups treated with 10-5 mol/L(high-dose group), 10-7 mol/L(medium-dose group)and 10-9 mol/L(low-dose group)bisphosphonate respectively, while the other was the control group without bisphosphonate in the medium. The adipocytes were identified by oil Red O stain seven days later. The adipocyte rate was measured by light absorption at 515 nm. The expression of PPARγ was measured by quantitative PCR. Comparisons between groups were tested by One-Way ANOVA analysis and t test. Results The average optical density of PPAR-gamma immunohistochemistry in the treatment group was less than the control group(P＜0.05). Seven days later, the absorbance between adipogenic induction group and low-dose group was not significant(P=0.167). but the adipogenic absorbance between the high-dose group, middle dose group and the control groups(P values were 0, 0.041). There was significant difference in the quantitative PCR results between the high-dose group, middle dose group and the expression of PPARγ adipogenic induction group(P value was 0, 0.01), but there was no significant differences between the low-dose group and adipogenic induction group(P＞0.05). Conclusion Effective concentrations of bisphosphonate can inhibit the expression of PPARγ which in turn lead to the suppression of hMSCs to the adipocytes. The glucocorticoid-induced osteoporosis is also depressed.

[Objective] To summarize the experience of Professor ZHANG Qin, a famous Chinese doctor in Zhejiang Province, in the treatment of dysmenorrhea by clinical syndrome differentiation. [Methods] Through the examples of teacher ZHANG's clinical treatment of primary dysmenorrhea and secondary dysmenorrhea in three cases, combined with the usual clinical experience of Professor ZHANG Qin to follow, analyze and summarize teacher ZHANG's clinical experience of the treatment of dysmenorrhea. [Results] Three cases show that, whether it is the primary dysmenorrhea or secondary dysmenorrhea, ZHANG believes that the total incidence of cold stagnation of Qi, blood circulation is not smooth, the main reason for the lack of collateral. A sense of cold dampness to menstrual wading, passengers in the cytoplasm, with warm and cold, blood, Tiaochong;with blood stasis, expelling, warming channels to dispel cold, removing blood stasis and relieving pain; also, liver blood deficiency and blood stasis of uterus, cure properly via removing film, streteving liver and removing stasis to relieve pain. Along with symptoms, with mild blood for treatment, in order to reconcile Qi and blood, Chongren unblocked. [Conclusion] Professor ZHANG Qin's experience in the treatment of dysmenorrhea by clinical syndrome differentiation has distinctive features and positive effects, so it is worth in-depth study and application.